Aveanna Healthcare stock rating reaffirmed at Outperform by William Blair

Aveanna reported Q4 2025 revenue of $662.5M (+27.4% YoY) and beat EPS by 30.77% and revenue consensus by 5.06%, yet the stock fell ~8% after the release (one-week decline ~8.9%). William Blair reiterated Outperform, noting the stock trades at ~10x adjusted EPS versus a 19x healthcare services peer average and sees modest upside to 2026 guidance; Raymond James upgraded to Strong Buy (PT $13) while Jefferies trimmed its PT to $10 but kept a Buy. Analysts and investors remain focused on the durability of Medicaid-driven growth and potential effects from the One Big Beautiful Bill Act, but William Blair considers these near-term concerns overstated.

Analysis

Market reaction to earnings-season noise in Medicaid-focused providers looks driven more by headline risk and cross-sectional de-risking than by a sudden change in durable service demand. The crowd is trading policy uncertainty and state-rate normalization as a binary outcome; that amplifies short-term volatility and creates asymmetric opportunities for names with intact operational leverage and visible margin progression.

Second-order winners are likely to be operators with diversified payor mixes, strong in-house care coordination, and scale that compresses unit labor cost volatility — they can steal share if smaller pure-play Medicaid providers retrench or de-leverage. Conversely, small-cap single-payor specialists will face tighter financing terms and higher M&A pressure, which could accelerate consolidation and create takeout optionality for well-capitalized buyers.

Key catalysts to watch over the next 3–12 months are state rate filings, company-level quarterly guidance cadence, and the phased operational effects of federal policy changes; any clarity that preserves prior growth assumptions should catalyze rapid re-rating. Tail risks include an unfavorable federal/state policy outcome or a sharp reversal in state rate trajectories combined with sustained labor cost inflation — those would compress multiples across the cohort and could take 12–24 months to fully play out.

Key Decisions for Investors

• Long AVAH equity (size 1–1.5% NAV) — horizon 6–12 months. Rationale: asymmetric upside from re-rating if guidance holds; tactical stop at 12% loss, take-profit at +35% to capture reversion of sentiment while keeping position size modest for policy tail risk.
• Relative-value pair: Long AVAH / Short ADUS (equal-dollar, net market-neutral, total exposure 2% NAV) — horizon 3–9 months. Rationale: isolate idiosyncratic sentiment dispersion within Medicaid providers; cut pair if both move against you by >15% or if sector-level negative policy print occurs.
• Defined-risk options: Buy 9–12 month AVAH call spread (buy near-the-money, sell higher strike) sized to equal ~1% NAV max loss. Rationale: captures re-rate with capped premium and favorable theta profile; target 3:1 upside-to-risk if sentiment normalizes.
• Tactical short (or buy puts) on smaller, single-payor Medicaid pure-plays (size 0.5–1% NAV) — horizon 6–18 months. Rationale: hedge against structural rate normalization and financing stress; limit exposure given regulatory tail risk and cover on two consecutive quarters of positive, organic growth guidance.